Replies to post #31849 on Ayala Pharmaceuticals Inc (ADXS)

[cab033]

2020-2021 has always been the expected BO date. Just look at when P3 will be complete. 2020. Why sell before P3 data is finalized? As a director of the company it would be foolish to sell out just before you cross the finish line. If the science works as good as everyone thinks it does, then they should take it all the way to the end. By now it is pretty obvious that ADXS is a pro at staying under the "early BO candidate" radar. I don't think there is anything to worry about there.